Iptacopan is being investigated as a treatment for IgA nephropathy. This study presents final data after 24 months of follow-up. IgA nephropathy is a kidney disease in which IgA immunoglobulin is deposited in the kidneys. The study was published in the New England Journal of Medicine. The aim was to evaluate the efficacy and safety of iptacopan in patients with IgA nephropathy. Data at 24 months provide information on the long-term effect of the treatment. The specific results of the study are available in the published article.